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Summary
Objective: To identify the major aggrecanase- and matrix metalloproteinase (MMP)-generated aggrecan fragments in human osteoarthritis
(OA) synovial ﬂuid and in human OA joint cartilage.
Method: Aggrecan fragments were prepared by CsCl gradient centrifugation. Fragment distributions were compared with aggrecanase-1
(ADAMTS-4) and MMP-3 digested human aggrecan by analysis with neoepitope antibodies and an anti-G1 domain antibody, using Western
immuno-blots.
Results: The overall fragment pattern of OA synovial ﬂuid aggrecan was similar to the fragment pattern of cartilage aggrecan cleaved in vitro
by ADAMTS-4. However, multiple glycosaminoglycan (GAG) containing aggrecanase and MMP-generated aggrecan fragments were identi-
ﬁed in OA synovial ﬂuid and some of these fragments were produced by the action of both types of proteinases. The synovial ﬂuid content of
large size aggrecan fragments with 374ARGS- and 342FFGV- N-terminals was about 107 and 40 pmoles per ml, respectively, out of a total
concentration of aggrecan fragments of about 185 pmoles per ml. OA synovial ﬂuid contained insigniﬁcant amounts of the G1-IPEN341 frag-
ment as compared to the G1-TEGE373 fragment, while OA cartilage contained signiﬁcant amounts of both fragments. OA cartilage contained
several GAG-containing aggrecan fragments with N-terminals of G1- or 342FFGV- but no fragments with an N-terminal of 374ARGS-.
Conclusions: The overall pattern of aggrecan fragments in human OA synovial ﬂuid and cartilage supports an important role for aggrecanase in
aggrecan degradation. However, the fragment patterns and their differential distribution between cartilage and synovial ﬂuid are consistent with
the existence of at least two proteolytic pathways for aggrecan degradation in human OA, generating both 342FFGV- and 374ARGS-fragments.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The gradual destruction of joint cartilage is a prominent fea-
ture of OA, involving loss from the tissue of the major matrix
components type II collagen and aggrecan. Aggrecan de-
pletion in arthritic joints is largely due to fragmentation of
the core protein by proteolysis. The involvement of aggreca-
nase in this process in human arthritis was ﬁrst shown by
the identiﬁcation in human arthritic synovial ﬂuids of high
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Received 1 November 2004; revision accepted 27 July 2005.10molecular weight (Mw) aggrecan fragments bearing the N-
terminal sequence 374ARGS-1,2a.
Multiple matrix metalloproteinase (MMP) and aggreca-
nase cleavage sites in the articular cartilage aggrecan have
since been identiﬁed by in vivo and in vitro studies of animal
and human samples (Fig. 1). Three MMP cleavage sites are
present in the interglobular domain (IGD), Asn341-Phe342
being the predominant MMP cleavage site4e7. One MMP
cleavage site has been identiﬁed between the G2 domain
and the keratan sulfate enriched region (KS)8, together with
several sites in the chondroitin sulfate enriched region one
(CS1)9. Several aggrecanase cleavage sites have been
identiﬁed in the aggrecan core protein: one in the IGD10e12
at Glu373-Ala374, other sites are located in the chondroitin
sulfate enriched region two (CS2) 10,11.
Only a limited number of studies have used human syno-
vial ﬂuid1,2,6,13,14 and human joint cartilage4,6,14,15 to char-
acterize the aggrecan fragments generated in OA. While
much of the current data suggest that destructive aggreca-
nolysis (i.e., in IGD) is due to aggrecanase activity1,2,6,14,
with ADAMTS-5 playing a lead role in mouse cartilage16,17,
other studies suggest that variable but quantitatively not
well determined proportions of the IGD cleavage may be
due to activity of MMP or other proteases13,15. Further,1
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Fig. 1. Schematic illustration of human aggrecan with cleavage sites of aggrecanases (above) and MMP (below). G1, G2 and G3 e globular
domains 1e3; IGD e interglobular domain; KS e keratan sulfate enriched region; CS1 and CS2 e chondroitin sulfate enriched region one and
two. Amino acid numberings are based on mature human aggrecan starting with the N-terminal sequence 1VETS- (NCBI accession nr
P16112). The cleavage sites represented by arrows were summarized from several publications (see text).deletion of the ADAMTS-5 catalytic domain in genetically
modiﬁed mice provided a partial but not complete protection
against cartilage destruction and aggrecan loss in OA and
arthritis models16,17. A better understanding of the relative
roles of the different proteolytic pathways is highly relevant
for current efforts to develop disease-modifying treatments
for human OA.
In the present study, we have identiﬁed aggrecan frag-
ments in pooled human OA cartilage and in pooled OA hu-
man synovial ﬂuid from a large number of patients with
varying stages of OA. A well-characterized set of antibodies
was used to detect and quantify both aggrecanase- and
MMP-generated aggrecan fragments. We detect for the ﬁrst
time in human samples large glycosaminoglycan (GAG) con-
taining fragments with an MMP-generated N-terminus of
342FFGV- both inOA synovial ﬂuid andOA cartilage, and pro-
pose mechanisms for aggrecan degradation in human knee
OA that incorporate the identiﬁed degradation patterns.
Materials and methods
MATERIALS
Alcian Blue 8GS (C.I. no 742240) was from Chroma-
Gesellschaft (Ko¨ngen, Germany). 4-(2-Aminoethyl)-benze-
nesulfonyl ﬂuoride (AEBSF), 6-aminohexonic acid (EACA),
benzamidineeHCl, BSA, chondroitin sulfate type C from
shark cartilage (C4384), tetrasodium ethylenediamine-
tetraacetate (Na4-EDTA), N-ethylmaleimide (NEM), trans-
epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E64),
iodoacetamide, o-phenathroline, pepstatin A and phenylme-
thylsulfonyl ﬂuoride (PMSF) were from Sigma. Chondroiti-
nase ABC (EC 4.2.2.4), keratanase (EC 3.2.1.103) and
keratanase II (from Bacillus sp. Ks36) were from Seikagaku.
Molecular weight markers 10e250 kDa (Precision Plus Pro-
tein Standards) were from BioRad, and for a 400 kDa Mw
marker reduced laminin from mouse EngelbretheHolm
Sarcoma (Roche) was used.
Activated recombinant human MMP-3 was provided by
Merck. Human recombinant ADAMTS-4 (a disintegrin and
metalloproteinase with thrombospondin motifs, aggreca-
nase-1) was provided by GlaxoSmithKline18. ECL Plus
detection and Hyperﬁlm-ECL were from Amersham
Biosciences. Mini gels (4e12 and 3e8%), lithium dodecylsulfate (LDS) sample buffer, sodium dodecyl sulfate
(SDS) running buffers (Tris-acetate and MOPS buffers),
and transfer buffer were all NuPAGE from Invitrogen.
Poly vinylidene diﬂuoride (PVDF) membranes were from
Invitrogen. Non-fat dry milk (Semper) was from the local
supermarket. Neo-speciﬁc rabbit anti-peptide sera anti-
KEEE, anti-FFGV, anti-LGQR, anti-TEGE and anti-IPEN
were prepared at Merck. Neo-speciﬁc anti-ARGS monoclo-
nal antibody (mab OA-1) was raised in mouse against
the synthetic peptide ARGSVILTVK (GlaxoSmithKline).
Neo-speciﬁc polyclonal anti-SELE antibody was raised in
rabbit against the synthetic peptide CASTASELE (Glaxo-
SmithKline). Anti-G1 antibody (polyclonal rabbit anti-
ATEGQV- peptide sera) was a gift from Dr John Sandy
(Shriners Hospital and University of South Florida, Tampa).
Polyclonal anti-aggrecan-G3 antibody was from Afﬁnity Bio-
Reagents (Golden, CO, USA). Anti-chondroitin sulfate (CS)
antibody (mab 3-B-3) was from Seikagaku. Peroxidase con-
jugated secondary antibodies, goat anti-mouse IgG was
from Cell Signaling Technology, goat anti-rabbit IgG from
KPL and goat anti-mouse IgM from Sigma. Synthetic pepti-
des used in immuno-blocking experiments, neoepitope pep-
tide ARGSVILTVKGGC, neoepitope peptide CASTASELE
and spanning peptide DIPENFFGVGGEEDC, were
from GlaxoSmithKline; spanning peptide EVVTASTASE-
LEGRGT, neoepitope peptide FFGVGGEEDITVC, neoepi-
tope peptide CEVAPTTFKEEE and spanning peptide
VAPTTFKEEEGLGS were from Innovagen (Lund, Sweden);
spanning peptide EGEARGSVILTVKPIF was from Merck;
anti-G1 blocking peptide CATEGQVRVNSIYQDKVSL was
a kind gift from Dr John Sandy.
HUMAN CARTILAGE AND SYNOVIAL FLUID SAMPLES
Knee cartilage was obtained from patients undergoing
joint replacement surgery for OA. All remaining cartilage
was removed from 10 knee joints, diced and pooled for ag-
grecan extraction. Samples were stored at 80(C. Synovial
ﬂuid samples from more than 100 patients with advanced
knee OA or with varying stages of post-injury cartilage
changes were pooled and then stored at 80(C. The syno-
vial ﬂuids and the cartilage samples were not from the same
subjects. All procedures were approved by the ethics review
committee of the Medical Faculty of Lund University.
103Osteoarthritis and Cartilage Vol. 14, No. 2AGGRECAN ISOLATION FROM SYNOVIAL FLUID
Human synovial ﬂuid pool (in 50 mM Na-acetate, pH 6.8)
was cleared by centrifugation (20 400! g, 35 min, 4(C),
and guanidineeHCl (4 M ﬁnal concentration) and CsCl
(starting density 1.5 g/ml) were added to the supernatant.
A CsCl density gradient centrifugation was performed
(162 000! g, 48 h, 16(C) and the D1-fraction (bottom
two-ﬁfth) was collected, dialyzed against Millipore-water
(Type I, 18.2 MU cm), and freeze-dried. This sample, called
SF-D1, was stored at20(C. An associative (without guani-
dineeHCl) A1-fraction, called SF-A1, was also made from
the human synovial ﬂuid pool, using the same method and
the same starting density. Both the associative and the dis-
sociative preparations were conducted either in the absence
or in the presence of proteinase inhibitors, 10 mM Na4-ED-
TA, 0.4 mM AEBSF, 1 mM pepstatin A, 5 mM E64 and
5 mM o-phenathroline (in gradient centrifugation) and
10 mM Na4-EDTA, 0.4 mM PMSF, 1 mM pepstatin
A, 100 mM iodoacetamide and 2 mM o-phenathroline (in
dialysis).
AGGRECAN ISOLATION FROM CARTILAGE
Aggrecan from a knee cartilage pool of 10 OA patients
was extracted with guanidineeHCl (4 M) in the presence
of proteinase inhibitors (10 mM Na4-EDTA, 100 mM EACA,
10 mM NEM, 5 mM benzamidineeHCl and 5 mM PMSF)
and then isolated by associativeedissociative CsCl density
gradient centrifugation, in the presence of the proteinase in-
hibitors, as described15. No hyaluronan (HA) was added.
Fractions A1D1 and A1D3 were collected (herein called car-
tilage-A1D1 and cartilage-A1D3) and ﬁnally dialyzed
against either Millipore water or against Millipore water con-
taining proteinase inhibitors (5 mM Na4-EDTA, 10 mM EA-
CA, 2 mM NEM, 2 mM benzamidineeHCl and 0.4 mM
PMSF) prior to freeze drying.
GAG AND PROTEIN QUANTITATION
The method for quantitation of GAG by Alcian Blue
precipitation was modiﬁed from Bjo¨rnsson19. Samples
and chondroitin sulfate standards (75 ml) were preci-
pitated for 2 h at 4(C with 0.04% w/v Alcian Blue, 0.72 M
guanidineeHCl, 0.25% w/v Triton X-100, and 0.1% v/v
H2SO4 (0.45 ml). The precipitates were collected as pellets
at 16 000! g 15 min, 4(C and then dissolved in 4 M
guanidineeHCl, 33% v/v 1-propanol (0.25 ml) prior to
absorbance measurement.
The protein quantitation method was modiﬁed from the
PierceMicro BCAAssayemicroplate procedure. Samples
and bovine serum albumin (BSA) standards were incubated
with bicinchoninic acid (BCA) on a 96-well microtiter plate
at 60(C for 1 h. After room temperature equilibration the ab-
sorbance was measured at 570 nm with a plate reader.
PROTEINASE DIGESTION OF CARTILAGE AGGRECAN
IN VITRO
Human aggrecan cartilage-A1D1 (1.5 nmol) was di-
gested for 16 h at 37(C with recombinant human MMP-3
(0.353 nmol) in proteinase digestion buffer (50 mM Trise
HCl, 100 mM NaCl, 10 mM CaCl2, pH 7.5). Human aggre-
can cartilage-A1D1 (856 pmol) was digested for 3 h at
37(C with recombinant human ADAMTS-4 (5.13 pmol) in
the same buffer. The enzymatic digestion reactions(1 ml) were stopped by addition of EDTA (18.3 mmol) and
were directly deglycosylated (see below). The molar calcu-
lations were based on a dry weight molecular mass for hu-
man aggrecan assuming 1000 kDa, for MMP-3 the Mw
used was 42.8 kDa and for ADAMTS-4 we used an Mw
of 60 kDa.
DEGLYCOSYLATION
Aggrecan in deglycosylation buffer (50 mM Tris-acetate,
50 mM Na-acetate, 10 mM EDTA, pH 7.6) was ﬁrst digested
for 2 h at 37(C with chondroitinase ABC (1 mU/mg GAG),
and then digested for another hour at 37(C with the addition
of keratanase (1 mU/mg GAG) in the presence of 1 mM
AEBSF and 10 mM NEM. Finally, the aggrecan was di-
gested at pH 6.0 for 1 h at 37(C with the addition of kerata-
nase II (0.1 mU/mg GAG). The deglycosylated samples
were dried in a vacuum centrifuge and dissolved in 2! con-
centrated sample buffer.
WESTERN IMMUNO-BLOT ANALYSIS
Deglycosylated samples (0.5e5 mg GAG per 5 mm well)
were denatured in 1! sample buffer under reducing
conditions (50 mM DTT) by boiling for 5 min. Samples were
separated (according to manufacturer’s instructions) by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) on either 3e8% Tris-acetate gels or 4e12%
BiseTris gels. Proteins were electrophoretically transferred
at room temperature at 40 V for 70 min (from 3 to 8% gels)
or at 35 V for 65 min (from 4 to 12% gels) onto PVDF mem-
branes (0.2 mm). After transfer, membranes were dried
completely at room temperature. Immuno-reactions were
conducted according to the ECL Plus instruction manual
(Amersham Biosciences) using ﬁlm for detection. Mem-
branes were washed in TBST-150 (20 mM TriseHCl,
150 mM NaCl, 0.1% v/v Tween 20, pH 7.6) four times at
each step using 4 ml/cm2. Blocking was conducted in block-
ing buffer (5% w/v non-fat dried milk in TBST-150), and an-
tibody incubations were done in blocking buffer for 1 h at
room temperature. For the anti-G1 immuno-reaction, the
washes were conducted in TBST-300 (20 mM TriseHCl,
300 mM NaCl, 0.1% v/v Tween 20, pH 7.6), blocking was
conducted in 3% w/v BSA (in TBST-300), and antibody in-
cubations were conducted in 1% w/v BSA (in TBST-300).
The following primary antibodies were used: anti-KEEE
(1:2000 or 1:5000 dilution), anti-FFGV (1:1000 or 1:2000 di-
lution), anti-LGQR (1:500 or 1:1000 dilution), anti-TEGE
(1:3000 dilution), anti-IPEN (1:10 000 dilution), anti-ARGS
(1:4000 dilution, 2.7 mg/ml), anti-SELE (1:1000 dilution,
1.2 mg/ml), anti-G1 (1:2000 or 1:5000 dilution), anti-G3
(1:500 dilution) and anti-CS stubs (1:3000 dilution). The fol-
lowing secondary peroxidase conjugated antibodies were
used: goat anti-mouse IgG (1:50 000 and 1:15 000 dilutions,
2.5 or 0.75 ng/ml), goat anti-rabbit IgG (1:400 000 and
1:75 000 dilutions 2.5 or 13.3 ng/ml) and goat anti-mouse
IgM (1:100 000 dilution). In the peptide blocking experi-
ments the peptide and the antibody were incubated simulta-
neously with the blotted proteins.
QUANTIFICATION OF FFGV- AND ARGS-FRAGMENTS
The complete conversion of GAG containing G1-
fragments to either FFGV- or ARGS-fragments (with
corresponding G1-IPEN and G1-TEGE fragments) was
achieved by digesting (as described above) cartilage
A1D1-fraction for 16 h with MMP-3 or by digesting for 24 h
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used as FFGV- or ARGS-standards in the Western blot
quantiﬁcation. The standards were assumed to contain
1 nmol FFGV- or ARGS-fragments per mg aggrecan dry
weight, using an Mw of 1! 106 g/mol aggrecan. The sy-
novial ﬂuid sample (D1-fraction) and standards were probed
by anti-ARGS or anti-FFGV antibodies as described above.
The detection and quantiﬁcationwas conducted in a lumines-
cence image analyzer (Fujiﬁlm LAS-1000) using Image
Gauge version 4.0 (Fujiﬁlm) software. Samples and stand-
ards were used within a linear range of the imaging system,
and the total sum of FFGV- or ARGS- immuno-signal was
used in the quantiﬁcation.
IDENTIFICATION OF AGGRECAN FRAGMENTS IN SYNOVIAL
FLUID AND CARTILAGE
Most of the CsCl-puriﬁed aggrecan fragments were im-
muno-identiﬁed at both N- and C-terminal ends. Fragments
that were not immuno-veriﬁed at both ends were further
characterized by Mw calculations, based on their migration
in the PAGE-system, together with a speciﬁc calibration
constant (A Struglics, S Larsson, LS Lohmander unpub-
lished). The calibration constant (K ) was generated from
several aggrecan fragments identiﬁed at both N- and C-
terminal ends by dividing the SDS-PAGE Mw (m) with thesum of the total amino acid Mw (a) and the total Mw of
GAG stubs ( g): KZm/(aC g).
Results
CHARACTERIZATION OF ANTIBODIES USING IN VITRO
DIGESTED CARTILAGE AGGRECAN AND BLOCKING PEPTIDES
Several aggrecan fragments were detected in the
ADAMTS-4 and MMP-3 in vitro digested cartilage-A1D1
samples (Fig. 2). The N- and C-terminal sequences of these
aggrecan fragments were identiﬁed in matching Western im-
muno-blot experiments (Table I). The anti-ARGS, anti-
SELE, anti-KEEE and anti-FFGV neoepitope antibody im-
muno-reactions were completely blocked by the speciﬁc
neoepitope peptides [Fig. 2(AeD)]. Little or no blocking of
the neoepitope immuno-reactions was observed in the pres-
ence of the corresponding spanning peptides [Fig. 2(AeD)].
The anti-G1 immuno-reactions were completely blocked by
the corresponding immunization peptide [Fig. 2(E)], and this
antibody has been further described20,21. The anti-ARGS
antibody (mab OA-1) has been further characterized by
Western and enzyme linked immunosorbent assay (ELISA)
experiments (Pratta et al., unpublished), whereas character-
ization of anti-TEGE and anti-IPEN neoepitope antibodies
was published22.Anti-ARGSA
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Fig. 2. Western immuno-blot peptide blocking experiment against in vitro digested cartilage aggrecan. Human cartilage aggrecan (A1D1) di-
gested in vitro with ADAMTS-4 (A, B, C, E lanes 1 and 3) or with MMP-3 (D, E lanes 2 and 4) was SDS-PAGE separated (3e8% gels) and
analyzed by Western immuno-blot in the presence or absence of synthetic peptides. (A) Anti-ARGS Western with 1.5 mg GAG per lane,G10-
mM neoepitope ARGSVILTVKGGC-peptide andG10-mM spanning EGEARGSVILTVKPIF-peptide. (B) Anti-SELE Western with 1.25 mg GAG
per lane, G2-mM neoepitope CASTASELE-peptide and G2-mM spanning EVVTASTASELEGRGT-peptide. (C) Anti-KEEE Western with
3.6 mg GAG per lane, G2-mM neoepitope CEVAPTTFKEEE-peptide and G2-mM spanning VAPTTFKEEEGLGS-peptide. (D) Anti-FFGV
Western with 4.2 mg GAG/lane, G10-mM neoepitope FFGVGGEEDITVC-peptide and G10-mM spanning DIPENFFGVGGEEDC-peptide.
(E) Anti-G1 Western with 4.2 mg GAG per lane,G2-mM immunization CATEGQVRVNSIYQDKVSL-peptide. Mean values of Mw of aggrecan
fragments are given as kDa, and were calculated based on electrophoretic migration. The anti-G1A band, marked with # (E) was identiﬁed as
the deglycosylation enzyme chondroitinase ABC (results not shown).
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Aggrecan fragments detected by Western immuno-blot in samples from OA patients
Aggrecan
fragments
SF-A1
fraction
SF-D1
fraction
Cartilage-A1D1
fraction
Cartilage-A1D3
fraction
Cartilage-A1D1 fraction
in vitro digested with
ADAMTS-4 MMP-3
G1-IPEN341 52 e e 52 e 51
G1-TEGE373 65 e e 65 64 e
342FFGV-G2-KS 80-95 e e e e 77
342FFGV-G2-CS1 e e 300 e 283 124, 166, 290
342FFGV-G2-SELE1545 e 310 e e 312 e
342FFGV-G2-KEEE1714 341 335 340 e 328 e
342FFGV-G2-G3 e e 411 e e e
374ARGS-G2-CS1 e 129-159 e e 122-158 e
374ARGS-G2-SELE1545 e 311 e e 309 e
G1-G2-KS ND e e ND e 134
G1-G2-CS1 e 200, 252 197, 217 ND 247 173, 213, 245
G1-G2-SELE1545 e 340 331 e 337 e
G1-G2-KEEE1714 e 354 367 e 353 e
G1-G2-G3 e e 429 e e e
1920LGQR-G3 e 103 e e 104 e
1546GRGT-KEEE1714 46 50 e e 51 e
Mw of detected aggrecan fragments from electrophoresis as mean values in kDa.
e, Not detected; ND, not determined.Peptide crossover experiments were conducted, testing,
e.g., anti-SELE immuno-reaction in the presence of ARGS-
VIL-peptide. None of these experiments showed false pos-
itive immuno-blocking (results not shown).
The HRP conjugated secondary antibodies used in this
paper did not bind directly to the blotted proteins in our
Western immuno-blot experiment systems (results not
shown). Further, the neoepitope antibodies used did not
bind to human IgG, BSA, MMP-3, ADAMTS-4, deglycosyla-
tion enzymes or Mw markers (results not shown). The
anti-G1 antibody showed immuno-reactivity against a
100 kDa non-aggrecan polypeptide which is marked as #
in [Fig. 2(E)].
These ﬁndings show that the antibodies used were spe-
ciﬁc for the neoepitopes and sequences examined.
THE EFFECT OF PROTEINASE INHIBITORS DURING THE
PURIFICATION AND DIALYSIS OF AGGRECAN
It was reported that guanidineeHCl denatured MMPs
could be activated during dialysis against distilled water23.
Therefore, we compared aggrecan puriﬁcation from human
synovial ﬂuid and cartilage in the presence or absence of
proteinase inhibitors in (a) the dialysis against distilled water
for cartilage aggrecan puriﬁcations, and (b) all steps of the
puriﬁcation of aggrecan from synovial ﬂuid (see Materials
and methods). The results showed similar immuno-patterns
and equal fragment intensities independent of the presence
or absence of proteinase inhibitors (result not shown).
These results indicate the absence of proteolysis during
preparation of aggrecan fragments from joint cartilage or sy-
novial ﬂuid as done here. The aggrecan fragments detected
in this report are thus likely to have originated from in vivo
aggrecanolysis.
SIMILARITIES BETWEEN AGGRECAN SPECIES DETECTED IN
HUMAN OA SYNOVIAL FLUID AND AGGRECAN FRAGMENTS
PREPARED FROM ADAMTS-4 IN VITRO DIGESTED HUMAN
JOINT CARTILAGE
Western analysis of unpuriﬁed synovial ﬂuid provided lit-
tle or no information on the aggrecan fragment content(result not shown), presumably due to the low concentration
of GAG-containing aggrecan fragments, together with high
concentration of protein and HA in synovial ﬂuid. We there-
fore puriﬁed high density D1 and A1 fractions of aggrecan
fragments from pooled human synovial ﬂuid using CsCl
density gradient centrifugation. Based on Western analysis
using an antibody which detects the products associated
with the aggrecan core protein following chondroitinase
ABC digestion (mab 3-B-3), the immuno-reactivity patterns
of the aggrecan fragments detected in human OA synovial
ﬂuid D1-fraction showed a high degree of similarity to the
ADAMTS-4 in vitro cleaved human cartilage-A1D1 sample,
but not with an MMP-3 digested sample (Fig. 3). The aggre-
can fragments detected by anti-ARGS, anti-SELE, anti-
KEEE and anti-LGQR antibodies in the OA synovial ﬂuid
D1-fraction were also observed in the ADAMTS-4 in vitro
cleaved cartilage-A1D1 sample. Not only did these samples
show the same patterns with the different antibodies, but
the aggrecan fragments from the two samples also showed
similar Mw (Table I). A difference observed in these compar-
ison experiments was that the ADAMTS-4 in vitro digested
cartilage-A1D1 sample contained a low Mw (51 kDa) anti-
KEEE fragment, most likely 1546GRGT-KEEE1714, which is
not seen in the synovial ﬂuid D1-fraction (Fig. 3), although
this fragment was observed in other preparations of the
OA synovial ﬂuid D1-fraction (results not shown). In contrast,
the aggrecan fragment pattern of the OA synovial ﬂuid sam-
ple differed signiﬁcantly from the aggrecan fragment pattern
of MMP-3 in vitro digested cartilage-A1D1 and from the car-
tilage-A1D1 sample (Table I).
These results suggest that the majority of the aggrecan
fragments identiﬁed in human OA synovial ﬂuid are gener-
ated from in vivo aggrecanase activity.
AGGRECAN FRAGMENTS DETECTED IN HUMAN OA SYNOVIAL
FLUID ARE GENERATED FROM BOTH AGGRECANASE AND
MMP ACTIVITIES
GAG-containing aggrecan fragments in the OA synovial
ﬂuid (D1-fraction) were identiﬁed in Western immuno-blot
experiments by using anti-G1 and neoepitope antibodies
(Fig. 4). To determine the likely N- and C-terminal
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C4 = Cartilage-A1D1 in vitro digested with ADAMTS-4
C3 = Cartilage-A1D1 in vitro digested with MMP-3
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Fig. 3. Aggrecan fragments detected in MMP-3 and ADAMTS-4 in vitro digested A1D1-cartilage, and in OA synovial ﬂuid (D1-fraction) by
Western immuno-blot. The samples were SDS-PAGE separated (3e8% gel) and analyzed by Western blot with different antibodies as shown.
Different amounts of GAG per lane were loaded to facilitate the comparison between the samples. The positions of Mw (in KDa) are indicated.
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were used. Firstly, the Western immuno-blot experiments
were repeated several times with the different antibodies
to give average values for the Mw of the aggrecan frag-
ments. Secondly, the lanes on the PVDF membranes were
divided in half after transfer, incubated with different anti-
bodies, and physically realigned before detection.
The neoepitope antibodies veriﬁed both aggrecanase
and MMP-generated N-terminal fragments in the OA syno-
vial ﬂuid (Fig. 4). Several G1-domain containing fragments
including G1-SELE1545 (340 kDa) and G1-KEEE1714
(354 kDa) were observed. The two 342FFGV-fragments ob-
served, 310 kDa and 335 kDa, contained aggrecanase gen-
erated C-terminal -SELE1545 and -KEEE1714 [Fig. 4(B)].
The faster migrating anti-SELE immuno-band was
composed of 374ARGS-SELE1545 and 342FFGV-SELE1545
fragments having similar Mw (Fig. 4). The multiple
374ARGS-CS1971e1352 fragments (129e159 kDa) and two
G1-CS1971e1352 fragments (200 kDa and 252 kDa) had their
C-terminal sequences identiﬁed as -GVED971e1352, from the
multiple MMP-3 cleavage site GVED971e1352Y972e1353ISGL
(see Fig. 1). Small amounts of low Mw 342FFGV-fragments
(80e95 kDa) were detected in the SF-A1 fraction, while only
trace amounts of these fragments were found in the SF-D1
fraction of OA synovial ﬂuid (results not shown). Such low
Mw 342FFGV-fragments have also been detected in Q-Se-
pharose puriﬁed synovial ﬂuids13. A weakly reacting
50 kDa anti-KEEE fragment, most like 1546GRGT-KEEE1714,
was detected in SF-D1 and SF-A1 samples of the OA syno-
vial ﬂuid pool (results not shown, Table I). This fragment has
previously been detected in normal human synovial ﬂuids14.
The 1920LGQR-G3 fragment detected in SF-D1 samples
was N-terminally (Fig. 3) and C-terminally (result not shown)
veriﬁed, and except for the C-terminals in 374ARGS- and
G1-CS1971e1352 fragments and the N-terminal of the G1-
KEEE1714 fragment, all the high Mw SF-D1 fragments de-
tected were immuno-veriﬁed both N- and C-terminally
(Fig. 4).
These results show that OA synovial ﬂuid contains at
least nine different GAG-containing aggrecanase and
MMP-generated fragments. Several of these fragments
were likely produced by the action of both proteinases. In
contrast to other reports6,14, we detected for the ﬁrst time
large GAG containing 342FFGV-fragments in OA synovial
ﬂuid.G1-TEGE373 AND G1-IPEN341 FRAGMENTS WERE BOTH
DETECTED IN HUMAN OA CARTILAGE, BUT ONLY INSIGNIFI-
CANT AMOUNTS OF G1-IPEN341 AS COMPARED TO G1-TEGE373
WERE OBSERVED IN HUMAN OA SYNOVIAL FLUID
In order to detect G1-TEGE373 and G1-IPEN341 aggrecan
fragments we prepared an A1D3 fraction from the OA carti-
lage pool (cartilage-A1D3) and an A1-fraction from the OA
synovial ﬂuid pool (SF-A1). As control samples we used
ADAMTS-4 or MMP-3 in vitro digested cartilage-A1D1. Af-
ter in vitro digestion of the cartilage-A1D1, a 65 kDa G1-
TEGE373 fragment was detected in the ADAMTS-4 cleaved
sample, and a 52 kDa G1-IPEN341 fragment was observed
in the MMP-3 digested sample as veriﬁed by the anti-G1,
anti-TEGE and anti-IPEN immuno-reactions (Fig. 5). The
cartilage-A1D3 sample showed approximately equal immu-
noreactivities for the 65 kDa G1-TEGE373 and the 52 kDa
G1-IPEN341 fragments, whereas the SF-A1 sample showed
very low amounts of G1-IPEN341 as compared to the G1-
TEGE373 fragment (Fig. 5). Similar results were obtained
from experiments using DE52 cellulose (diaminoethylcellu-
lose) anion exchange14 puriﬁed aggrecan samples pre-
pared from the OA synovial ﬂuid pool (results not shown).
Further, when increasing amounts of G1-IPEN341 fragments
were added to SF-A1 samples, there was a corresponding
increase in IPEN-neoepitope immuno-reactivity, suggesting
that the low amount of G1-IPEN341 fragment detected in sy-
novial ﬂuid was not due to inhibitory factors (results not
shown). The OA cartilage fraction A1D1 and the OA syno-
vial ﬂuid fraction D1 did not contain any G1-TEGE373 or
G1-IPEN341 fragments (results not shown).
These results, based on the -IPEN and -TEGE neoepitope
antibodies together with the G1-antibody, suggest that OA
synovial ﬂuid has a very low content of the G1-IPEN341 frag-
ment compared to the G1-TEGE373 fragment, but that OA
cartilage contains signiﬁcant amounts of both fragments.
GAG CONTAINING AGGRECAN FRAGMENTS DETECTED
IN HUMAN OA CARTILAGE
To detect high Mw GAG containing aggrecan fragments
in the pooled OA cartilage an A1D1 fraction was prepared.
No fragments with the N-terminal neoepitope ARGS were
detected in the cartilage-A1D1 (Fig. 6) or cartilage-A1D3
samples (results not shown). On the other hand, several
high Mw fragments with the N-terminal neoepitope FFGVSF = Synovial fluid A1-fraction
C = Cartilage-A1D3
MMP = Cartilage-A1D1 in vitro digested with MMP-3
TS4 = Cartilage-A1D1 in vitro digested with ADAMTS-4
G1 TEGE373
G1 IPEN341
Anti-G1 Anti-TEGE
— 65 kDa
— 52 kDa
Anti-IPEN
Protein (µg) 2.8 1.2 1.2 0.6 2.8 0.6 0.6 2.8 0.6 0.6
SF C MMP TS4 SF C TS4 SF C MMP
Fig. 5. Detection of aggrecan fragments G1-TEGE and G1-IPEN by Western immuno-blot. The human samples were SDS-PAGE separated
(4e12% gel) and analyzed by Western immuno-blot using different antibodies as shown. Amount of protein loaded per lane is shown. Mean
values of Mw of aggrecan fragments were calculated based on electrophoretic migration.
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A1D1 sample (Fig. 6). Two FFGV-containing aggrecan pol-
ypeptides were identiﬁed as a 411 kDa 342FFGV-G3 frag-
ment (also C-terminally veriﬁed, results not shown) and as
a 340 kDa 342FFGV-KEEE1714 fragment (Fig. 6 and Table
I). A 300 kDa 342FFGV-fragment had a CS1 located C-ter-
minal identiﬁed as -DLS1334e1453, from the calpain-2 site24
XDLS1334e1453Y1335e1454GLPS (Fig. 6 and Table I). In addi-
tion, several high Mw G1-fragments were observed in the
cartilage-A1D1 sample. Besides the 429 kDa full length
G1-G3 molecule (also veriﬁed C-terminally, results not
shown), the cartilage-A1D1 sample also contained
a 367 kDa G1-KEEE1714 fragment, a 331 kDa G1-SELE1545
fragment and two (197 and 217 kDa) G1-GVED971e1352
(-CS1) fragments (Fig. 6 and Table I). The 100 kDa false
positive anti-G1 immuno-band, derived from chondroitinase
ABC polypeptide (Fig. 2), was also observed in the carti-
lage-A1D1 sample (Fig. 6). No N-terminal LGQR-fragments
were observed in these cartilage samples (results not
shown).
These results show that several high Mw GAG containing
fragments with N-terminal sequences of either G1- or
342FFGV-, but not 374ARGS-, are present in the OA
cartilage.
FFGV- AND ARGS-FRAGMENTS WERE QUANTIFIED IN HUMAN
OA SYNOVIAL FLUID
OA synovial ﬂuid (D1-fraction) was quantiﬁed for content
of FFGV- or ARGS-fragments using FFGV- and ARGS-
standards, generated by MMP-3 or ADAMTS-4 total aggre-
can cartilage-A1D1 digests [as an example see Fig. 2(A
and D)], using Western immuno-blot and a luminescenceimaging system. The OA synovial ﬂuid contained 40.3 pmol
FFGV- and 107 pmol ARGS-fragments per ml neat synovial
ﬂuid, with an ARGS- to FFGV-fragment molar ratio of 2.7
(Table II). The GAG concentration in the human synovial
ﬂuid pool was 140 mg per ml. Based on the assumption that
75% of the aggrecan Mw represents GAG, the total amount
of aggrecan fragments per ml SF was 185 mg, or
185 pmoles assuming an Mw for aggrecan of 1! 106 g/
mol. Based on this quantiﬁcation, 20e25% of the GAG-con-
taining aggrecan fragments in pooled human OA synovial
ﬂuid carried the FFGV- N-terminal sequence, while the cor-
responding proportion carrying the ARGS-terminal was
55e60%.
Table II
Calculated amounts of ARGS and FFGV fragments in synovial fluid
from OA patients using Western immuno-blot
Synovial ﬂuid
pmol/ml SF nmol/mg GAG
ARGS-fragments 107 (17.6) 1.13 (0.2)
FFGV-fragments 40.3 (9.4) 0.42 (0.1)
ARGS/FFGV (mol/mol) 2.7
Total amount of aggrecan 185 pmol/ml SF
SF-D1 samples were probed with anti-ARGS or anti-FFGV anti-
bodies. The samples were quantiﬁed using total ADAMTS-4 or
MMP-3 cartilage-A1D1 digests as standards. Values are expressed
as the amount of fragments per volume SF (neat synovial ﬂuid) or
amounts of fragments per mg GAG in the SF-D1 fraction. The data
show total amounts of respective fragment, standard deviation val-
ues are shown in brackets for which nZ 8.
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Our understanding of aggrecan degradation pathways in
vivo in human OA is based on samples from a small number
of patients1,2,6,13,14. By pooling synovial ﬂuids from more
than a hundred OA patients, we have identiﬁed the major
aggrecan fragments present in knee OA synovial ﬂuid, inde-
pendent of disease stage, age, and other variables that
might inﬂuence fragment patterns in the individual patient.
Due to ethical constraints the human joint cartilage used
was limited to that from knee replacement surgery, and sub-
ject origin was separate from the origin of the synovial ﬂuid
pool. However, the joint cartilage pool included a range of
samples from the macroscopically normal to that with ad-
vanced OA pathology. The OA synovial ﬂuid results pre-
sented in this paper were obtained from several D1- and
A1-fraction preparations, and the OA cartilage data were
obtained from two separate A1D1/A1D3 preparations, all
providing reproducible results. Using Western immuno-blot,
we detected no differences in the aggrecan fragment pat-
terns or intensities of cartilage and synovial ﬂuid samples
when the puriﬁcation was done in the presence or absence
of proteinase inhibitors. This contrasts to a previous report,
where aggrecanolysis by MMPs was observed during the
dialysis step in the absence of proteinase inhibitors when
guanidineeHCl was removed from extracts of cultured pig
cartilage23. However, the cartilage explants used in that
study were stimulated in vitro with IL-1, which would be ex-
pected to signiﬁcantly upregulate protease expression and
activity.
All the antibodies used were carefully tested for false pos-
itive recognition. We characterized the aggrecan fragments
by identiﬁcation of both N- and C-terminal sequences using
Western immuno-blot and by size calculation based on
electrophoretic migration.
Although the OA synovial ﬂuid contained several aggre-
can fragments generated by both aggrecanases and
MMPs, and some that were generated only by MMP (Table
I), it is evident from the Western immuno-blots that the ag-
grecan fragment pattern in OA synovial ﬂuid was mainly
generated by aggrecanase activity (Fig. 3; Table I). It has
been suggested that ADAMTS-4 at high concentrations in
vitro may cleave aggrecan at Asn341-Phe342, in addition to
the preferred Glu373-Ala374 site25. At the protease concen-
trations used in the present study we were unable to repli-
cate these ﬁndings (Table I).
The differential distribution of aggrecan fragments be-
tween OA cartilage and OA synovial ﬂuid (Table I, Fig. 7)
may be caused by several different, but not mutually exclu-
sive, processes, including but not limited to those discussed
here. Firstly, aggrecan structure is variable. For example,
newly synthesized molecules are likely to have an intact
G3-domain while older aggrecan molecules appear to be in-
creasingly truncated at the C-terminal end. This heteroge-
neity of the aggrecan core protein will inﬂuence the
behavior of fragments once cleaved, for example, through
interaction of the G3-domain with other matrix compo-
nents26. Further, variability of aggrecan carbohydrate sub-
stitution may affect protease susceptibility27. It is unclear
to what extent aggregation varies, but this may also inﬂu-
ence aggrecan fragment behavior. Secondly, with more
than one protease involved in degradation, there is potential
for differential protease activation and substrate speciﬁcity,
the latter inﬂuenced by the order of cleavage. Further poten-
tial for variability in aggrecan degradation pathways may be
provided by C-terminal processing of ADAMTS-4 which was
shown to inﬂuence its binding to extracellular matrixcomponents and substrate speciﬁcity28. ADAMTS-4 is in-
hibited by TIMP-3 and by interaction with ﬁbronectin, provid-
ing yet other possibilities for protease regulation29,30.
Thirdly, the differential distribution of aggrecan subpopula-
tions and proteolytic activities within the cartilage matrix
and synovial ﬂuid will likely play an important role in gener-
ating the observed distribution. For example, molecules of
different ages may be differentially distributed within the car-
tilage matrix, and newly synthesized molecules with an in-
tact G3-domain may be preferentially located close to the
chondrocytes in the territorial matrix, while older, truncated
molecules may dominate in the interterritorial matrix.
Fourthly, cellular uptake mechanisms may differentiate be-
tween different molecular fragments.
Since we detected in human OA cartilage both aggreca-
nase-generated G1-TEGE373 and MMP-generated G1-
IPEN341 fragments (Fig. 5), their distal counterparts, carry-
ing the neoepitopes 374ARGS- and 342FFGV-, must both
have been produced in the tissue. There was, however,
a striking difference in the distribution of these fragments
between cartilage and synovial ﬂuid. The MMP-generated
342FFGV-fragments were partly retained in cartilage (Tables
I, II; Figs. 6, 7), whereas the aggrecanase-generated
374ARGS-fragments were not found in the tissue but only
in the synovial ﬂuid [Table I; Figs. 4(A), 6, 7]. Quantiﬁcation
showed that the OA synovial ﬂuid pool contained
107 pmoles per ml of 374ARGS-fragments (Table II). This
amount corresponds to approximately 60% of the total
amount of aggrecan fragments in human OA synovial ﬂuid
(estimated to 185 pmoles/ml), and corroborates earlier ﬁnd-
ings in arthritic synovial ﬂuids1,2.
Although the possibility exists that the 374ARGS-frag-
ments detected in the synovial ﬂuid are the result of aggre-
canase activity in the joint cavity, we suggest that these
fragments are a product of aggrecanase cleavage of mole-
cules within the cartilage that lack the G3-domain. When
such G3-truncated fragments are detached from the HA in-
teracting G1-domain by aggrecanase cleavage, diffusion in-
to the joint cavity may occur. Consistent with this proposal,
all the 374ARGS-fragments detected in the OA synovial ﬂuid
lacked the G3-domain (Figs. 4, 7). Cartilage explant experi-
ments have shown that 374ARGS-fragments readily migrate
out into the culture media, resulting in very low 374ARGS-
neoepitope content in the tissue6,31. On the other hand,
a possible association between the KS enriched regions
of aggrecan and type II collagen has been reported32,33,
which could act to retain these fragments in the cartilage.
Endocytosis by chondrocytes of 374ARGS-neoepitope frag-
ments may also occur, although an HA-G1 complex is re-
quired for the endocytosis34.
The partial retention in the cartilage of the large 342FFGV-
G3 fragments (Figs. 6, 7), where the G3-domain may inter-
act with ﬁbulin-2 and other matrix molecules26, could be
explained if aggrecan molecules attacked by MMPs were
preferentially those newly synthesized and still retaining
their G3-domain. It is more difﬁcult to explain the matrix re-
tention of the G3-truncated FFGV-fragments 342FFGV-CS1
and 342FFGV-KEEE1714 (Fig. 6). Since 374ARGS-fragments
of similar sizes are detected in synovial ﬂuid, but not in the
cartilage (Table I; Fig. 6), neither the G2-domain nor the KS
and CS enriched regions seem to mediate this tissue reten-
tion. The 342FFGV-neoepitope itself or the N- and O-linked
substitutions located between Phe342 and Glu373 within the
IGD could be the mediators of this retention35,36. In support,
synovial ﬂuid low Mw 342FFGV-fragments (80e95 kDa) mi-
grated in the associative CsCl gradient to the bottom A1-
fractions (Table I), which indicates an association between
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synovial ﬂuid (D1 and A1 samples). Fragments shown are generated by pathways initiated by aggrecanase action (A) and MMP-action (B)
as shown in Fig. 8.these fragments and HA or other molecules binding to HA.
Partial matrix retention of G3-truncated 342FFGV-fragments
has been reported37. Previously detected FFGV-fragments
in human OA synovial ﬂuid13,38 and in porcine cartilage37
were a mixture of several smaller peptides ranging between
40 and 200 kDa. In contrast, we detected large (O 300 kDa)
342FFGV-aggrecan fragments in the OA synovial ﬂuid
and OA cartilage [Figs. 4(B), 6]. The level of the large
342FFGV-aggrecan fragments in the OA synovial ﬂuid pool
was about 40 pmol per ml, or 20e25% of the total amount
of aggrecan fragments (Table II). This compares with previ-
ous ﬁndings of 10e20 pmol per ml OA synovial ﬂuid, where
a competitive ELISA using the FFGV-epitope mab AF28
was used to detect low Mw FFGV-fragments13.
We readily detected both G1-TEGE373 and G1-IPEN341
fragments in OA cartilage (Fig. 5), similar to previous
reports using Western analysis6,14,15 or immunohistochem-
istry15. However, we detected insigniﬁcant amounts of G1-
IPEN341 fragments in the OA synovial ﬂuid with anti-G1 oranti-IPEN antibodies, while G1-TEGE373 was readily de-
tected with both anti-G1 and anti-TEGE antibodies. Even
though the sensitivity and afﬁnity of the anti-TEGE and an-
ti-IPEN neoepitope antibodies may differ, these results to-
gether with the results based on anti-G1 Western analysis
show that there were insigniﬁcant amounts of G1-IPEN341
fragments in the OA synovial ﬂuid pool as compared to
the OA cartilage pool (Fig. 5). This contrasts to other reports
that have detected both -TEGE373 and -IPEN341 neoepi-
topes in some individual OA synovial ﬂuid samples, al-
though the quantity of the -TEGE373 neoepitope was
greater14.
There are at least two possible explanations for relative
paucity of G1-IPEN341 fragments in the OA synovial ﬂuid,
one not necessarily excluding the other. Firstly, after MMP
cleavage at the -IPEN341Y342FFGV- site, which could have
occurred either in the matrix with subsequent diffusion of
the fragments into the joint cavity or within the joint cavity,
the G1-IPEN341 fragments were immediately degraded
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is possible that the majority of -IPEN341Y342FFGV- cleav-
age takes place within the pericellular or territorial matrix,
with prompt internalization of the -IPEN341 neoepitope by
the chondrocytes. Endocytosis of the -TEGE373 neoepitope
has been shown to occur in a porcine cartilage explant sys-
tem37, and a similar process may occur with the -IPEN341
neoepitope.
With regard to spatial localization of proteinase activities,
it was shown by immunohistochemistry that even though
both -TEGE373 and -IPEN341 neoepitopes were present in
OA cartilage, the -IPEN341 neoepitope was reduced or ab-
sent from the most superﬁcial parts of the articular carti-
lage, while the -TEGE373 neoepitope was present in the
same location15. This may indicate that aggrecanase
cleavage can be spatially distinct within the tissue from
MMP cleavage. Early work suggested that in normal ma-
ture cartilage there are at least two metabolic pools of ag-
grecan e an active pool with short-lived aggrecan
surrounding the chondrocytes and an inactive pool with
long-lived aggrecan in the interterritorial matrix39e43. This
is consistent with -TEGE373Y374ARGS-cleavage occurring
in the interterritorial matrix, where fragment diffusion into
the joint cavity may dominate, while the majority of cleav-
age at -IPEN341Y342FFGV- takes place in the pericellular
or territorial matrix where endocytosis may dominate. Suchseparate pathways have been proposed15, and are further
supported by in vitro studies showing that aggreca-
nases are unable to cleave 342FFGV-fragments at the
-TEGE373Y374ARGS- site37.
The ﬁndings described here provide a basis for a model
of aggrecan turnover in OA joint cartilage (Fig. 8). The path-
way generating 374ARGS-fragments is initiated by aggreca-
nase action in the interterritorial matrix, generating
aggrecan with variable C-terminal sequences, but still inter-
acting with HA and link protein. These interterritorially locat-
ed molecules are further cleaved by aggrecanase within the
IGD, generating G1-TEGE373 fragments bound to HA and
free unattached 374ARGS-fragments. An associated but
yet little understood simultaneous degradation of HA may
allow the release of G1-TEGE373 from the matrix11,44.
The pathway for the generation of 342FFGV-fragments is
initiated in the vicinity of metabolically active chondrocytes
when newly synthesized aggregated proteoglycans are
cleaved within the IGD by MMP, generating G1-IPEN341
and 342FFGV-G3 fragments. G1-IPEN341 fragments, bound
to HA, are further processed by the chondrocytes. The
342FFGV-G3 fragments, bound within the matrix by interac-
tions with the N- and C-terminal sequences, are cleaved
in the CS2 region by aggrecanase generating 342FFGV-
fragments with variable C-terminals. Finally, the model
suggests that the different G3-truncated 374ARGS- andFURTHER
PROCESSING
Chondrocyte
SYNTHESIS
AGNASE cut
in CS2
AGNASE cut
in IGD
HA
G1
G2
G3
G1 G2
G3
G1
G2
G3
FIB
UL
IN
HA
G1 IPEN
IPEN G2
G2
G2
G3
G3
G3 FI
BU
LI
N
FFGV
FFGV
FFGV
(II)
Aggrecanase activity in the
interterritorial matrix
G1 G2
G1 G2
HA
SELE
KEEE
G1
G1
HA
TEGE
TEGE
G2ARGS
G2ARGS
MMP cut
in IGD
G2
FFGV
(I)
MMP activity in the
pericellular matrix
ENDOCYTOSIS
AGNASE cut
in CS2
G1
Fig. 8. A hypothetical model of the major proteolysis of cartilage aggrecan in OA joints. ARGS- and FFGV-fragments are generated by two
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further processed and then diffuse into the joint cavity.
In summary, the results of the present study indicate that
the degradation of aggrecan in human knee OA cartilage in-
volves both MMPs and aggrecanases, albeit with an appar-
ent dominant role for aggrecanases. Further examination of
individual samples of human OA cartilage and synovial ﬂuid
with quantitative methods may provide information on indi-
vidual variability relating to these pathways, as well as their
relationship to age, disease stage and disease activity; in-
formation that may be relevant when considering therapies
directed towards preventing cartilage matrix breakdown.
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